Tag - IPA

Developments

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and...

January 22, 2025

Markets

HCW starts ImmunoPrecise Antibodies at buy; PT $9

H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies (NASDAQ:IPA) with a “buy” rating and price target of $9. The stock closed at $4.93 on Dec. 1. ImmunoPrecise is a contract research organization (CRO) that...

December 2, 2022

Tag - IPA

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

HCW starts ImmunoPrecise Antibodies at buy; PT $9

General

More